CHENGDU, China, Oct. 27 /Xinhua-PRNewswire-FirstCall/ -- Tianyin Pharmaceutical, Co., Inc., (AMEX:TPI), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that the Company will present at the Rodman & Renshaw Annual Global Investment Conference on Tuesday, November 11th, 2008. The Conference will be held on November 10th-12th at New York Palace Hotel in New York City.
The Company's presentation will take place in the Henry Salon (5th Floor) at 12:00 p.m. EST. Dr. Guoqing Jiang, Tianyin's Chairman and CEO, Mr. Allen Tang, assistant to the CEO, and Mr. Stewart Lor, a member of the Board of Directors, will be representing Tianyin at the conference and will be available for one-on-one meetings with analysts and investors throughout the day.
Management will discuss the Company's current product portfolio, development pipeline, research and development platform, recent financial highlights and its long term growth strategy.
Participation is by invitation and registration is mandatory. For more information on the conference contact your Rodman & Renshaw representative or visit http://www.rodmanandrenshaw.com/.
About Tianyin Pharmaceuticals Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 33 modernized TCMs and 4 generic western medicines in the market, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance Program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 48 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 720 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,384 employees. Tianyin achieved revenue of approximately $33.5 million and net income of approximately $6 million in FY2008 ending June 30, 2008. For more information about Tianyin, please visit http://www.tianyinpharma.com/ Safe Harbor Statement This Press Release contains or may contain forward looking statements and information that are based upon beliefs of and information currently available to the Company's management as well as estimates and assumptions made by the Company's management. When used herein the words "anticipate", "believe", "estimate", "expect", "future", "intend", "plan" and similar expressions as they relate to the Company or the Company's management identify forward looking statements. These statements involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, intended or planned.
For more information, please contact: For the Company:
Allen Tang, Ph.D., MBA, Assistant to the CEO
China 15821225642
Investors:
HC International, Inc. Alan Sheinwald
US (914) 669-0222
DATASOURCE: Tianyin Pharmaceutical (TPI) CONTACT: Allen Tang, Ph.D., MBA, Assistant to the CEO, Tianyin Pharmaceuticals, China 15821225642, ; Investors: Alan Sheinwald, HC International, Inc., +1-914-669-0222, , for Tianyin Pharmaceutical Web site: http://www.tianyinpharma.com/ http://www.rodmanandrenshaw.com/
|